Oseltamivir-resistant influenza A(H1N1)pdm09 virus in southern Brazil

Marx, Camila; Gregianini, Tatiana Schäffer; Lehmann, Fernanda Kieling Moreira; Lunge, Vagner Ricardo; Carli, Sílvia De; Dambrós, Bibiana Paula; Tumioto, Gabriela Luchiari; Seadi, Claudete Farina; Fonseca, André Salvador Kazantzi; Ikuta, Nilo

doi:10.1590/s0074-02762013000300021

Cited by 6 publications

(4 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study that analyzed samples from a different region of Brazil aiming the monitoring of antiviral resistance to neuraminidase inhibitors showed that the prevalence of mutants did not support the detection of resistance strains of A(H1N1)pdm09 virus during 2009-2010 [8]. Another study that analyzed only samples from RS found a low prevalence of the mutations H275Y and S247N of the NA protein in strains circulating between 2009-2011 [9]. In a recent study with Brazilian clinical samples, Ferreira et al showed a significant association between the D239G substitutions in the haemagglutinin (HA) gene of pandemic influenza A H1N1 virus with mortality [10].…”

Section: Discussionmentioning

confidence: 99%

Epidemiological Profile of Influenza A Cases in Southern Brazil in the Post-Pandemic Period

Baccin¹

2013

J Antivir Antiretrovir

View full text Add to dashboard Cite

Influenza viruses are highly contagious and circulate in all geographical regions. During the 2009 pandemics caused by influenza A(H1N1), the State of Rio Grande do Sul (RS) was the first to detected A(H1N1) cases. In 2010, a broad vaccination program was applied in RS when 44.9% of the population joined the program. During the 2011, a total of 1,433 samples were sent to the Central Laboratory in Porto Alegre (LACEN-RS) for viral detection by qRT-PCR. Only 107 (7.5%) cases of the A(H1N1) virus were confirmed versus 182 (12.7%) cases of seasonal influenza A. The incidence of both influenza types virus was higher in patients aged 0-10 years old. The median viral load was higher in patients infected with seasonal, in comparison to those infected with A(H1N1) virus contrary of pandemic period. In 2011 most of the patients that were infected by influenza A virus (79%, p<0.001), did not receive vaccine. The presence of fever, cough, dyspnea, myalgia and rhinorrhea were the most frequent symptoms (positivity >60%). Furthermore in 2011 only patients infected by pandemic virus died (12.9%, p=0.001) in contrast with 2009 pandemic period when 6% of patients infected by pandemic virus died. In other hand in the whole population (5.3%) the mortality rate was similar that observed in pandemic period (5.9%). These analyses about epidemiological and molecular data provide important scenery about the characteristics of the host-pathogen interaction after massive exposure during pandemic period.

show abstract

Section: Discussionmentioning

confidence: 99%

Epidemiological Profile of Influenza A Cases in Southern Brazil in the Post-Pandemic Period

Baccin¹

2013

J Antivir Antiretrovir

View full text Add to dashboard Cite

show abstract

“…Clinical samples from 6,918 SARS cases notified by 204 hospitals (representing 66% of the state hospitals) were analyzed from January 2009 to December 2011. Influenza virus A was detected using RT-qPCR 3,33 , and influenza virus B, hRSV, ADV, and PIV 1, 2, and 3 were detected using indirect immunofluorescence assay (IFA) (Light Diagnostic TM Respiratory Panel 1 Viral Screening and Identification kit, Merck Millipore ® , Darmstadt, Germany). In total, 3,495 samples presented negative result for all these viruses, and by convenience sampling, 545 (20%) were selected for hMPV detection (Figure 1).…”

Section: Samplingmentioning

confidence: 99%

Human metapneumovirus in Southern Brazil

Gregianini

Seadi

Menegolla

et al. 2018

Rev. Soc. Bras. Med. Trop.

Self Cite

View full text Add to dashboard Cite

show abstract

“…The resistance to the antiviral drugs has been reported in quite a few numbers of cases worldwide [11]. Various studies have shown the H1N1 resistant to the Oseltamivir, requiring the use of Zanamivir as the drug of choice in these patients [4,12,13]. Resistance to Oseltamivir is commonly seen in patients who were exposed to the drug previously and also in immunecompromised patients (hematological malignancies, chronic renal or liver failure).…”

Section: Introductionmentioning

confidence: 99%

“…Patients suffering from severe and complicated H1N1 influenza pneumonia (mostly seen in immunecompromised patients like post transplant patients, hematological malignancies), the recommended dose of Oseltamivir is twice the standard dosing, that is 150mg twice daily and that too for longer duration of 10 days (standard therapy is for 5 days) [4,[10][11][12][13][14]. This longer and higher dose treatment is required taking into consideration the decreased enteral absorption of Oseltamavir in critically ill patients and also the prolonged duration of viral replication and shedding seen in these patients [14].…”

Section: Introductionmentioning

confidence: 99%

Swine Flu (H1N1 Influenza A): A concise review

2017

IJIRM

View full text Add to dashboard Cite

The H1N1 influenza A, also known as swine flu, has caused widespread panic not only in India, but across the world. It emerged as pandemic in 2009 and made the whole world realize its dreadful presence. Early diagnosis, identification of the risk factors and prompt antiviral treatment along with preventive measure, including vaccination and chemoprophylaxis are the mainstay of management and can help in containment of this deadly disease. The authors give a concise review of the H1N1 influenza A.

show abstract

Oseltamivir-resistant influenza A(H1N1)pdm09 virus in southern Brazil

Cited by 6 publications

References 14 publications

Epidemiological Profile of Influenza A Cases in Southern Brazil in the Post-Pandemic Period

Epidemiological Profile of Influenza A Cases in Southern Brazil in the Post-Pandemic Period

Human metapneumovirus in Southern Brazil

Swine Flu (H1N1 Influenza A): A concise review

Contact Info

Product

Resources

About